10 episodes

Medical oncologist Dr Neil Love interviews preeminent oncology clinical investigators on new research, COVID-19 updates and how it all comes together in general medical oncology practice.

Oncology Today with Dr Neil Love Research To Practice

    • Medicine

Medical oncologist Dr Neil Love interviews preeminent oncology clinical investigators on new research, COVID-19 updates and how it all comes together in general medical oncology practice.

    Dr Michael Pishvaian Comments on the Use of PARP Inhibition in the Management of Pancreatic Cancer

    Dr Michael Pishvaian Comments on the Use of PARP Inhibition in the Management of Pancreatic Cancer

    Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease.


    Additional Resources



    Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317-27. Full text
    Burris HA 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-13. Abstract
    Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. Correspondence
    Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. Full text
    Doleh Y et al. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Cancer Med 2020;9:3463-76. Full text
    Mavros MN et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: A population-based analysis. CMAJ 2019;191(21):E574-80. Full text
    Lowery MA et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. JNCI 2018;110(10):1067-74. Full text
    O’Reilly EM et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38(13):1378-88. Full text

    • 15 min
    Dr Jeff Sharman Comments on the Use of BTK Inhibitors as Treatment for Patients with SARS-CoV-2

    Dr Jeff Sharman Comments on the Use of BTK Inhibitors as Treatment for Patients with SARS-CoV-2

    Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2.


    Additional Resources



    Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract
    AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release]. April 14, 2020.
    Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract
    COVID-19 and CLL: Frequently Asked Questions. Hematology.org. May 6, 2020;Version 1.3.
    Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. Correspondence
    Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. Correspondence
    Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. Full text

    • 27 min
    Oncology Nurse Practitioner Kelly Goodwin Provides a Nurse’s Perspective on Clinical Care for Patients with Lung Cancer at Massachusetts General Hospital During COVID-19

    Oncology Nurse Practitioner Kelly Goodwin Provides a Nurse’s Perspective on Clinical Care for Patients with Lung Cancer at Massachusetts General Hospital During COVID-19

    Oncology nurse practitioner Kelly Goodwin discusses current treatment practices at Massachusetts General Hospital, the challenges encountered treating patients with cancer during COVID-19, and the use of telemedicine in oncology care.


    Additional Resources



    Catlin N. Navigating the COVID-19 pandemic as an oncology nurse. Oncology Times 2020;42(8):1,12,17. https://journals.lww.com/oncology-times/Fulltext/2020/04200/Protecting_Cancer_Patients_During_the_Coronavirus.1.aspx
    Paterson C et al. Oncology nursing during a pandemic: Critical reflections in the context of COVID-19. Semin Oncol Nurs 2020;[Online ahead of print]. Abstract
    Pelin C et al. Safety at the time of the COVID-19 pandemic: How to keep our oncology patients and healthcare workers safe. J Natl Compr Canc Netw 2020;[Online ahead of print]. Abstract

    • 16 min
    Dr Benjamin Levy on the Management of Lung Cancer in the COVID-19 Era

    Dr Benjamin Levy on the Management of Lung Cancer in the COVID-19 Era

    Dr Benjamin Levy from Johns Hopkins comments on changes to the surgical and targeted treatment of lung cancer during COVID-19 and challenges in the management of immune-related adverse events with immune checkpoint inhibitors.


    RTP Lung Cancer Summit Presentations


    Additional Resources



    Banna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020;5(2). Abstract

    Kumar S et al. Alternative multidisciplinary management options for locally advanced non-small cell lung cancer during the COVID-19 global pandemic. J Thorac Oncol 2020;[Online ahead of print]. Abstract

    Thoracic Surgery Outcomes Research Network, Inc. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;[Online ahead of print]. Abstract

    • 19 min
    Dr Kathleen Moore Comments on the Management of Ovarian Cancer During the COVID-19 Pandemic

    Dr Kathleen Moore Comments on the Management of Ovarian Cancer During the COVID-19 Pandemic

    Dr Kathleen Moore from the Stephenson Cancer Cetner and co-chair of the SGO 2020 Annual Meeting discusses COVID guidelines and the impact of the pandemic on clinical research and the treatment of ovarian cancer.



    Akladios C et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN Group for the CNGOF. J Gynecol Obstet Hum Reprod 2020;[Online ahead of print]. Abstract
    Dowdy S, Fader AN. Surgical considerations for gynecologic oncologists during the COVID-19 pandemic. SGO 2020. https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/surgical-considerations-for-gynecologic-oncologists-during-the-covid-19-pandemic/
    Monk B et al. COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. Gynecol Oncol 2020;[Online ahead of print]. Abstract
    Mueller B. Telemedicine arrives in the UK: '10 years of change in one week.' New York Times, April 4, 2020. https://www.nytimes.com/2020/04/04/world/europe/telemedicine-uk-coronavirus.html
    Ramirez PT et al. COVID-19 global pandemic: Options for management of gynecologic cancers. Int J Gynecol Cancer 2020;[Online ahead of print]. Abstract
    Society of Gynecologic Oncology. Gynecologic oncology considerations during the COVID-19 pandemic. https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/gyn-onc-considerations-during-covid-19/
    Society of Gynecologic Oncology. SGO 2020 Annual Meeting on Women’s Cancer. https://www.sgo.org/education/annual-meeting-on-womens-cancer/

    • 14 min
    Dr Julie Gralow Comments on Breast Cancer Management in Seattle during the COVID-19 Pandemic

    Dr Julie Gralow Comments on Breast Cancer Management in Seattle during the COVID-19 Pandemic

    Dr Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance, reviews how telemedicine and the screening, diagnosis and treatment of breast cancer have rapidly adapted based on resource limitations and risk factors related to COVID-19.


    Additional Resources



    Soran A et al. Breast cancer diagnosis, and follow-up during COVID-19 pandemic. Eur J Health 2020;16(2):86-8. Abstract
    American College of Surgeons. COVID-19 guidelines for triage of breast cancer patients. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer
    Falandry C et al. Challenges with the management of older patients with cancer during the COVID-19 pandemic. J Geriatri Oncol 2020;[Online ahead of print]. Abstract

    • 25 min

Top Podcasts In Medicine